Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II allogeneic PBPC transplantation with TLI/ATG conditioning for hematologic malignancies
2007-005563-10Phase 2Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Dec 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolic acid and antithymocyte globulin rabbit in hematopoietic malignancies, non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) and 8 more, sponsored by Fondazione EMN Italy. Primary endpoint: Incidence and severity of acute graft-versus-host disease. Started Dec 2007; status: completed.
02
Drugs
mycophenolic acidantithymocyte globulin rabbit
03
Conditions
hematopoietic malignanciesnon-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-005563-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005563-10.